EGFR and non-small cell lung carcinoma: On 21 May 2021, the FDA granted accelerated approval to amivantamab-vmjw for adult patients with locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations that progressed on or after platinum-based chemotherapy [49].